Stay updated with breaking news from Alkermes. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Alkermes (NASDAQ:ALKS – Get Free Report) issued an update on its FY 2024 earnings guidance on Friday morning. The company provided earnings per share guidance of 2.800-2.800 for the period, compared to the consensus earnings per share estimate of 2.520. The company issued revenue guidance of $1.5 billion-$1.6 billion, compared to the consensus revenue estimate […]
Alkermes plans to initiate phase 2 trials for its orexin-2 receptor agonist aimed at treating narcolepsy within the first half of the year.
Alkermes (NASDAQ:ALKS – Get Free Report) released its quarterly earnings data on Thursday. The company reported $0.22 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.51 by ($0.29), RTT News reports. The company had revenue of $377.50 million for the quarter, compared to the consensus estimate of $362.78 million. Alkermes had […]
Alkermes ( NASDAQ:ALKS ) Full Year 2023 Results Key Financial Results Revenue: US$1.66b (up 50% from FY 2022). Net...
Alkermes shows rising price performance, earning an upgrade to its IBD Relative Strength Rating The post Alkermes Stock Gets RS Rating Upgrade; Profits Surge…